file1,
file2, etc. all in the same folder or directory;
first, locate one of the files with the [Browse...] button. Then alter the
file path in the box above to include '*' character (eg. file*).
Wildcard '?' to blanket only one character works too.| Historiographs |
Grand Totals: LCS 7398, GCS 21737, CR 38784 Collection span: 1977 - 2012 | |
| Word(i) List (2518) Word count: 12056, All words count: 16977 | ||
| # | Word | Recs | TLCS | TGCS |
|---|---|---|---|---|
| 401 | REQUIRED | 4 | 37 | 87 |
| 402 | ALLOANTIGEN | 2 | 21 | 86 |
| 403 | HIGHER | 4 | 4 | 86 |
| 404 | MAJOR | 6 | 50 | 86 |
| 405 | STABILITY | 1 | 62 | 86 |
| 406 | TERM | 4 | 3 | 86 |
| 407 | RESPONSE | 12 | 43 | 85 |
| 408 | SITU | 8 | 45 | 85 |
| 409 | PARITY | 12 | 36 | 84 |
| 410 | CD34 | 10 | 34 | 83 |
| 411 | GRAVES | 3 | 72 | 83 |
| 412 | PEDIATRIC | 17 | 55 | 83 |
| 413 | BASIS | 5 | 28 | 82 |
| 414 | GENOMIC | 1 | 4 | 82 |
| 415 | HYPOREACTIVITY | 5 | 49 | 81 |
| 416 | TWO | 6 | 16 | 81 |
| 417 | DONORS | 12 | 11 | 80 |
| 418 | EXPRESSION | 11 | 8 | 80 |
| 419 | INACTIVATION | 3 | 16 | 80 |
| 420 | STATUS | 11 | 36 | 80 |
| 421 | AMNION | 1 | 3 | 79 |
| 422 | CHORION | 1 | 3 | 79 |
| 423 | FAMILY | 7 | 35 | 79 |
| 424 | SPLIT | 3 | 14 | 79 |
| 425 | CART | 1 | 1 | 78 |
| 426 | HORSE | 1 | 1 | 78 |
| 427 | PREDICT | 4 | 15 | 78 |
| 428 | PUTTING | 1 | 1 | 78 |
| 429 | REDUCTION | 1 | 1 | 78 |
| 430 | UNIVERSAL | 1 | 1 | 78 |
| # | Word | Recs | TLCS | TGCS |
| 431 | ARTICLE | 9 | 7 | 77 |
| 432 | INCIDENTAL | 3 | 43 | 77 |
| 433 | JAPANESE | 5 | 69 | 77 |
| 434 | SEX | 6 | 9 | 77 |
| 435 | SKEWED | 2 | 14 | 77 |
| 436 | ALLOGENIC | 2 | 2 | 76 |
| 437 | ALPHA | 4 | 1 | 76 |
| 438 | ASSESSMENT | 7 | 53 | 76 |
| 439 | CARDIOMYOCYTES | 3 | 0 | 76 |
| 440 | CONTINUED | 1 | 20 | 76 |
| 441 | STABLE | 5 | 33 | 76 |
| 442 | CUTTING | 1 | 59 | 75 |
| 443 | EDGE | 1 | 59 | 75 |
| 444 | FLUORESCENCE | 7 | 37 | 75 |
| 445 | RETRACTED | 2 | 5 | 75 |
| 446 | SEE | 2 | 5 | 75 |
| 447 | ACQUIRED | 9 | 34 | 74 |
| 448 | ACTIVE | 5 | 32 | 74 |
| 449 | ALLOTRANSPLANTATION | 6 | 9 | 74 |
| 450 | BABOONS | 5 | 1 | 74 |
| 451 | CLEAR | 1 | 35 | 74 |
| 452 | COMMON | 6 | 19 | 74 |
| 453 | CRITICALLY | 1 | 1 | 74 |
| 454 | FAS | 1 | 2 | 74 |
| 455 | ILL | 1 | 1 | 74 |
| 456 | IMMUNIZATION | 3 | 3 | 74 |
| 457 | INSIGHTS | 5 | 5 | 74 |
| 458 | MAY | 10 | 41 | 74 |
| 459 | NON-INVASIVE | 3 | 3 | 74 |
| 460 | PHENOMENON | 2 | 5 | 74 |
| # | Word | Recs | TLCS | TGCS |
| 461 | PRETREATMENT | 1 | 35 | 74 |
| 462 | SCIENTIFIC | 3 | 1 | 74 |
| 463 | TREATMENT | 11 | 14 | 74 |
| 464 | TWELVE | 1 | 7 | 74 |
| 465 | CTLA4IG-TREATED | 1 | 2 | 73 |
| 466 | ENGINEERED | 1 | 2 | 73 |
| 467 | NECESSARY | 1 | 2 | 73 |
| 468 | POPULATION-BASED | 5 | 8 | 73 |
| 469 | PROFILE | 2 | 49 | 73 |
| 470 | LEUKEMIA | 13 | 39 | 72 |
| 471 | OPPOSITE | 1 | 19 | 72 |
| 472 | RELATIONSHIP | 9 | 24 | 72 |
| 473 | REVERSE | 2 | 48 | 72 |
| 474 | ANTI-CD3 | 1 | 3 | 71 |
| 475 | BOVINE | 2 | 5 | 71 |
| 476 | DEOXYSPERGUALIN | 1 | 3 | 71 |
| 477 | DURABLE | 1 | 3 | 71 |
| 478 | IMMUNOTOXIN | 1 | 3 | 71 |
| 479 | MACAQUES | 2 | 3 | 71 |
| 480 | MARROW-DERIVED | 5 | 13 | 71 |
| 481 | NEPHROPATHY | 1 | 3 | 71 |
| 482 | PERITRANSPLANTATION | 1 | 3 | 71 |
| 483 | TERMINATION | 3 | 56 | 71 |
| 484 | EFFECTOR | 2 | 14 | 70 |
| 485 | HA-1-SPECIFIC | 1 | 14 | 70 |
| 486 | PARAFFIN-EMBEDDED | 3 | 52 | 70 |
| 487 | REGULATOR | 1 | 14 | 70 |
| 488 | SECTIONS | 2 | 52 | 70 |
| 489 | 6-BROMOHEXANOATE | 1 | 3 | 69 |
| 490 | ALBUMIN | 1 | 3 | 69 |
| # | Word | Recs | TLCS | TGCS |
| 491 | ANTIMITOCHONDRIAL | 1 | 3 | 69 |
| 492 | ASSAYS | 4 | 23 | 69 |
| 493 | BARRIER | 3 | 40 | 69 |
| 494 | CARCINOMA | 4 | 7 | 69 |
| 495 | CONJUGATE | 1 | 3 | 69 |
| 496 | PAROUS | 7 | 54 | 69 |
| 497 | REPORT | 9 | 4 | 69 |
| 498 | XENOBIOTIC | 1 | 3 | 69 |
| 499 | MULTI-LINEAGE | 1 | 48 | 68 |
| 500 | SUCCESSFUL | 11 | 44 | 68 |
| 501 | ANTIGEN-PRESENTING | 1 | 7 | 67 |
| 502 | ARTERIOPATHY | 1 | 7 | 67 |
| 503 | CONTRIBUTIONS | 1 | 7 | 67 |
| 504 | DISRUPTION | 1 | 7 | 67 |
| 505 | LYMPHATIC | 1 | 7 | 67 |
| 506 | OBLITERATIVE | 1 | 7 | 67 |
| 507 | TWINS | 6 | 24 | 67 |
| 508 | DONOR-STRAIN | 1 | 5 | 66 |
| 509 | NONMYELOABLATIVE | 4 | 8 | 66 |
| 510 | OCCURS | 4 | 34 | 66 |
| 511 | CELL-DEPLETED | 3 | 28 | 65 |
| 512 | GRAFT-VERSUS-HOST | 12 | 3 | 65 |
| 513 | REACTIVE | 3 | 43 | 65 |
| 514 | TH2-ORIENTED | 1 | 43 | 65 |
| 515 | URINE | 3 | 10 | 65 |
| 516 | CONGENITAL | 3 | 48 | 64 |
| 517 | HYPOTHYROIDISM | 1 | 1 | 64 |
| 518 | NIMA | 3 | 26 | 64 |
| 519 | REPRODUCTION | 6 | 4 | 64 |
| 520 | USE | 6 | 31 | 64 |
| # | Word | Recs | TLCS | TGCS |
| 521 | ETIOLOGY | 5 | 14 | 63 |
| 522 | LIVERS | 5 | 37 | 63 |
| 523 | LOSS | 6 | 40 | 63 |
| 524 | MONOSOMY | 2 | 10 | 63 |
| 525 | NONTRANSFUSED | 1 | 61 | 63 |
| 526 | PRETRANSPLANT | 6 | 30 | 63 |
| 527 | THERAPY | 13 | 15 | 63 |
| 528 | ANTI-CD40L | 3 | 5 | 62 |
| 529 | ARCHITECTURE | 1 | 0 | 62 |
| 530 | FEASIBILITY | 4 | 28 | 62 |
| 531 | FIBROSIS | 2 | 38 | 62 |
| 532 | HLA-SPECIFIC | 3 | 54 | 62 |
| 533 | IRRADIATION | 3 | 9 | 62 |
| 534 | MARKER | 3 | 10 | 62 |
| 535 | MEMBERS | 3 | 28 | 62 |
| 536 | SEX-SPECIFIC | 1 | 0 | 62 |
| 537 | DELETION | 4 | 27 | 61 |
| 538 | DERMATOMYOSITIS | 5 | 28 | 61 |
| 539 | EVENT | 4 | 19 | 61 |
| 540 | MOTHERS | 5 | 55 | 61 |
| 541 | TIME | 7 | 26 | 61 |
| 542 | FETOMATEMAL | 1 | 26 | 60 |
| 543 | HEMATOPOLETIC | 1 | 26 | 60 |
| 544 | RARE | 3 | 10 | 60 |
| 545 | VIEWS | 1 | 2 | 60 |
| 546 | CANINE | 9 | 6 | 59 |
| 547 | CONSEQUENCES | 4 | 32 | 59 |
| 548 | EXPLORATORY | 1 | 3 | 59 |
| 549 | GENE | 7 | 5 | 59 |
| 550 | HEMATOLOGIC | 3 | 37 | 59 |
| # | Word | Recs | TLCS | TGCS |
| 551 | MICROCHIMERISMS | 4 | 38 | 59 |
| 552 | NONHUMAN | 5 | 10 | 59 |
| 553 | IMMUNOLOGIC | 4 | 22 | 58 |
| 554 | MOLECULE | 3 | 4 | 58 |
| 555 | SEQUENCE-SPECIFIC | 6 | 42 | 58 |
| 556 | ABLE | 1 | 38 | 57 |
| 557 | BLOCKADE | 4 | 2 | 57 |
| 558 | BLOOD-BRAIN | 1 | 38 | 57 |
| 559 | CASE | 10 | 5 | 57 |
| 560 | CHLORIDE | 3 | 36 | 57 |
| 561 | CROSS | 1 | 38 | 57 |
| 562 | EARLY | 13 | 26 | 57 |
| 563 | MANIFESTATIONS | 2 | 2 | 57 |
| 564 | NUDE | 5 | 13 | 57 |
| 565 | PERIOD | 2 | 13 | 57 |
| 566 | ALLOREACTIVITY | 6 | 19 | 56 |
| 567 | BRIEF | 1 | 4 | 56 |
| 568 | BYPRODUCT | 1 | 29 | 56 |
| 569 | DECEASED-DONOR | 1 | 4 | 56 |
| 570 | EPITHELIAL | 4 | 5 | 56 |
| 571 | GVHD | 5 | 15 | 56 |
| 572 | IMPROVED | 3 | 12 | 56 |
| 573 | MATERNAL-FETAL | 4 | 38 | 56 |
| 574 | MODIFIED | 4 | 2 | 56 |
| 575 | MONITORING | 4 | 7 | 56 |
| 576 | MYOCARDIAL-TISSUE-SPECIFIC | 1 | 48 | 56 |
| 577 | ORGAN-SPECIFIC | 1 | 29 | 56 |
| 578 | PARTICIPANT | 1 | 29 | 56 |
| 579 | RESULTS | 9 | 12 | 56 |
| 580 | SIMULTANEOUS | 5 | 10 | 56 |
| # | Word | Recs | TLCS | TGCS |
| 581 | STATE | 3 | 33 | 56 |
| 582 | ACTIVATION | 3 | 1 | 55 |
| 583 | ASSISTED | 2 | 3 | 55 |
| 584 | ISOLATED | 6 | 3 | 55 |
| 585 | PROLIFERATION | 2 | 31 | 55 |
| 586 | REDUCED-INTENSITY | 5 | 26 | 55 |
| 587 | CAUCASIAN | 3 | 17 | 54 |
| 588 | CONDITIONING | 8 | 16 | 54 |
| 589 | CONTRIBUTION | 5 | 20 | 54 |
| 590 | FEMALES | 5 | 46 | 54 |
| 591 | IMMUNOSUPPRESSANTS | 1 | 6 | 54 |
| 592 | NEWBORN | 2 | 42 | 54 |
| 593 | NUMBERS | 2 | 36 | 54 |
| 594 | PLUS | 2 | 6 | 54 |
| 595 | REMODELING | 1 | 50 | 54 |
| 596 | REPRODUCTIVE | 5 | 15 | 54 |
| 597 | SIBLING | 10 | 20 | 54 |
| 598 | ACTIVATED | 4 | 8 | 53 |
| 599 | CONVERSION | 2 | 1 | 53 |
| 600 | DISORDERS | 6 | 40 | 53 |